These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2169785)

  • 1. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
    Tabona MV
    Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
    Chevallier B
    Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR; Serrou B; Caubel M
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
    Soukop M
    Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study].
    Golaszewski T; Kölbl H; Lahousen M; Staab HJ
    Wien Klin Wochenschr; 1995; 107(20):613-21. PubMed ID: 7502509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
    Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
    Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.
    Blower PR
    Eur J Cancer; 1990; 26 Suppl 1():S8-11. PubMed ID: 2169786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
    Hesketh PJ; Crews JR; Cohen R; Blackburn LM; Friedman CJ
    Cancer J; 2000; 6(3):157-61. PubMed ID: 10882331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
    Joss RA; Brand BC; Buser KS; Cerny T
    Eur J Cancer; 1990; 26 Suppl 1():S2-8. PubMed ID: 2169781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Granisetron, a new and potent antiemetic for treatment of cytostatic drug-induced vomiting in gynecological malignancies].
    Regidor PA; Schindler AE
    Geburtshilfe Frauenheilkd; 1994 Jan; 54(1):51-4. PubMed ID: 8150251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
    Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
    Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
    Carmichael J; Harris AL
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.